FDA lifts clinical hold on Repros' Proellex

06/13/2010 | Bloomberg Businessweek

The FDA approved Repros Therapeutics' request to conduct another trial of Proellex for use in reducing menstrual bleeding associated with uterine fibroids and endometriosis, lifting a clinical hold that was placed on the drug candidate last year because of liver toxicity. The drugmaker will test lower doses of Proellex on 12 women in a 10-week study comparing the drug with placebo.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC